Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022785 | 0.84 | CHRNB2 (0.34) | LTA4HCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18209875 | 0.81 | LTA4H (0.32) | LTA4H | |
| SCHEMBL20028851 | 0.81 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL20028324 | 0.79 | SMO (0.37) | LTA4HKMT2ASMO | |
| SCHEMBL20028321 | 0.78 | KMT2A (0.38) | MEN1KMT2A | |
| SCHEMBL20028911 | 0.77 | BRD4 (0.32) | MEN1KMT2A | |
| SCHEMBL18215014 | 0.75 | FAAH (0.38) | — | |
| SCHEMBL20022822 | 0.75 | — | — | |
| SCHEMBL20028325 | 0.73 | SMO (0.36) | LTA4HKMT2ASMO | |
| SCHEMBL9772117 | 0.71 | SMO (0.36) | LTA4HKMT2ASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292125-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-09-04 | — | — | EP | disclosed |
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | LTA4H 58/4885CHRNB2 4832/4885CHRNB4 4842/4885 |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | LTA4H 58/4885CHRNB2 4832/4885CHRNB4 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.